Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2024-08-12 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
关于2024年半年度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (299 characters) from the company about the disclosure of its 2024 half-year report. It states that the half-year report and its summary have been published on an official disclosure website and invites investors to review it. There is no actual financial data or detailed report content included in this document. According to the 'MENU VS MEAL' rule, such a brief notice that a report has been published is classified as a Report Publication Announcement (RPA), not the report itself (IR).
2024-08-12 Chinese
关于召开2024年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting (临时股东会) of shareholders for 新天地药业股份有限公司. It includes information about the meeting date, time, venue, voting procedures (both onsite and online), registration details, agenda items to be voted on, and proxy forms. There is no financial data or report content, but rather an announcement and instructions related to the shareholder meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document is over 5,000 characters and contains detailed meeting and voting information, not just a brief announcement or a report publication notice. Therefore, the correct classification is PSI.
2024-08-12 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and shareholder information for the half-year period. The presence of substantive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is 3418 characters, which is relatively short, but it contains actual financial figures and not just an announcement or a link to a report. Therefore, it should be classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-12 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report". It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, and asset values for the first half of 2024. It also includes sections like "管理层讨论与分析" (Management Discussion and Analysis), company business overview, financial indicators, and risk disclosures. The length is substantial (15,000 characters), and the content includes actual financial statements and substantive analysis rather than just an announcement or summary. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-12 Chinese
华泰联合证券有限责任公司关于新天地药业股份有限公司使用部分超募资金永久补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (华泰联合证券有限责任公司) regarding the use of part of the over-raised funds by 新天地药业股份有限公司 to permanently supplement working capital. It includes detailed information about the fundraising, investment projects, approvals by various company committees (audit committee, independent directors, board of directors, supervisory board), and compliance with regulatory requirements. The document is not a full financial report but rather a formal opinion and verification related to the use of funds raised in an IPO. It does not contain financial statements or quarterly/yearly financial results. It is also not a simple announcement or notice but a formal verification report by the sponsor. This fits best under the category of Regulatory Filings (RNS) as it is a compliance-related filing that does not fit into other specific categories like Annual Report, Interim Report, or Capital/Financing Update. The document length is under 5,000 characters, but it contains substantive content beyond a mere announcement, so it is not a Report Publication Announcement (RPA).
2024-08-12 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Xintiandi Pharmaceutical Co., Ltd. regarding the approval of several agenda items including the 2024 semi-annual report, a special report on the use of raised funds, and other related financial and operational matters. It references the existence of the actual 2024 semi-annual report and other reports being disclosed on an external website (cninfo.com.cn), indicating that this document itself is not the report but an announcement of the meeting resolutions approving these reports. The document length is short (1640 characters) and it mainly serves as a formal announcement of meeting decisions rather than containing substantive financial data or the full report content. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than the actual Interim/Quarterly Report (IR) or Annual Report (10-K).
2024-08-12 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.